Quest Partners LLC Has $175,000 Stock Position in CareDx, Inc (NASDAQ:CDNA)

Quest Partners LLC lifted its position in shares of CareDx, Inc (NASDAQ:CDNA) by 37.8% in the third quarter, Holdings Channel reports. The institutional investor owned 5,611 shares of the company’s stock after acquiring an additional 1,540 shares during the period. Quest Partners LLC’s holdings in CareDx were worth $175,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently modified their holdings of CDNA. GAMMA Investing LLC increased its position in shares of CareDx by 1,021.8% in the second quarter. GAMMA Investing LLC now owns 2,210 shares of the company’s stock worth $34,000 after purchasing an additional 2,013 shares during the period. Plato Investment Management Ltd bought a new position in shares of CareDx in the second quarter worth $62,000. KBC Group NV bought a new position in shares of CareDx in the third quarter worth $99,000. nVerses Capital LLC increased its position in shares of CareDx by 175.0% in the third quarter. nVerses Capital LLC now owns 3,300 shares of the company’s stock worth $103,000 after purchasing an additional 2,100 shares during the period. Finally, Meeder Asset Management Inc. bought a new position in shares of CareDx in the second quarter worth $142,000.

Analyst Ratings Changes

A number of research analysts recently commented on CDNA shares. The Goldman Sachs Group raised their price target on CareDx from $26.00 to $35.00 and gave the stock a “buy” rating in a research report on Wednesday, October 16th. StockNews.com upgraded CareDx from a “hold” rating to a “buy” rating in a research report on Thursday, October 17th. BTIG Research decreased their target price on CareDx from $40.00 to $35.00 and set a “buy” rating on the stock in a research report on Tuesday, November 5th. Craig Hallum lifted their target price on CareDx from $22.00 to $32.00 and gave the company a “buy” rating in a research report on Thursday, August 1st. Finally, HC Wainwright reiterated a “neutral” rating on shares of CareDx in a research report on Tuesday, October 22nd. One analyst has rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, CareDx currently has a consensus rating of “Moderate Buy” and an average price target of $29.60.

CareDx Stock Down 0.8 %

CareDx stock opened at $24.91 on Thursday. CareDx, Inc has a 12-month low of $7.42 and a 12-month high of $34.84. The business’s 50-day moving average price is $25.84 and its two-hundred day moving average price is $22.39. The stock has a market cap of $1.34 billion, a PE ratio of -9.30 and a beta of 1.80.

CareDx (NASDAQ:CDNA) last released its quarterly earnings results on Monday, November 4th. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.11. The company had revenue of $82.88 million for the quarter, compared to analysts’ expectations of $80.04 million. CareDx had a negative return on equity of 53.70% and a negative net margin of 45.90%. The business’s quarterly revenue was up 23.4% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.43) earnings per share. As a group, analysts expect that CareDx, Inc will post -0.7 earnings per share for the current year.

CareDx Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.